SCHEMBL7969172

SCHEMBL7969172

O=C1N(c2ccccc2)CCN1c1nc2ccc(Cl)cc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
TP53 P04637 2/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
GFER P55789 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALKBH3 Q96Q83 2/20 0.51
NPY5R Q15761 4/20 0.49
TRPC3 Q13507 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3791087 0.90 NPC1 (0.47) NPC1RAB9ATP53HPGDTSHR
SCHEMBL7962507 0.85 NPY5R (0.60) NPC1RAB9AALKBH3NPY5RMEN1
SCHEMBL10140665 0.83 MEN1 (0.45) NPC1RAB9AALKBH3NPY5RMEN1
SCHEMBL7962503 0.82 NPY5R (0.52) NPC1RAB9ANPY5RMEN1KMT2A
SCHEMBL7970001 0.82 GFER (0.56) NPC1RAB9ATP53HPGDTSHR
SCHEMBL7973223 0.82 NPY5R (0.62) ALKBH3NPY5REGLN1ADRA1AKCNH2
SCHEMBL7973969 0.81 CHEK2 (0.57) NPY5R
SCHEMBL7976233 0.80 PRSS1 (0.52) NPY5R
SCHEMBL7973178 0.76 NPY5R (0.56) HPGDNPY5RMEN1KMT2AKDM4E
SCHEMBL13219451 0.75 NPY5R (0.79) NPC1RAB9ATP53HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed
WO-2009143039-A2 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 NPC1 1029/4885RAB9A 400/4885TP53 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.